Allergy Therapeutics PLC AGYTF의 지난 분기 매출 실적은 어땠나요?
Allergy Therapeutics PLC의 매출 추정치는 얼마인가요?
Allergy Therapeutics PLC의 수익 품질 점수는 얼마인가요?
Allergy Therapeutics PLC는 언제 수익을 보고하나요?
Allergy Therapeutics PLC의 예상 수익은 얼마인가요?
Allergy Therapeutics PLC은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.11
시가
$0.11
일일 범위
$0.11 - $0.11
52주 범위
$0.052 - $0.11
거래량
15.0K
평균 거래량
241
EPS(TTM)
-0.01
배당수익률
--
시가총액
$675.5M
AGYTF란 무엇인가요?
Allergy Therapeutics Plc is a biotechnology company, which engages in the Research and Development of allergy treatments. The company is headquartered in Worthing, West Sussex and currently employs 602 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. The company sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.